ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
Counterfiat
|
200 |
80K |
10 |
08:25 |
08:25 |
ASX - By Stock
|
200
|
80K
|
10
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Counterfiat
|
527 |
175K |
6 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
527
|
175K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Counterfiat
|
527 |
175K |
15 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
527
|
175K
|
15
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Counterfiat
|
21K |
7.2M |
1 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
21K
|
7.2M
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Counterfiat
|
527 |
175K |
2 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
527
|
175K
|
2
|
|
ASX - By Stock
|
PYC Biotech |
Re:
PYC Chart and Technical Analysis
|
|
Counterfiat
|
148 |
66K |
6 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
148
|
66K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
Counterfiat
|
200 |
80K |
9 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
200
|
80K
|
9
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
Counterfiat
|
200 |
80K |
4 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
200
|
80K
|
4
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Change in substantial holding
|
|
Counterfiat
|
7 |
3.6K |
1 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
7
|
3.6K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Change in substantial holding
|
|
Counterfiat
|
7 |
3.6K |
3 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
7
|
3.6K
|
3
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Successful GLP Tox Studies in Second Blinding Eye Disease
|
|
Counterfiat
|
21 |
9.1K |
7 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
21
|
9.1K
|
7
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Successful GLP Tox Studies in Second Blinding Eye Disease
|
|
Counterfiat
|
21 |
9.1K |
6 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
21
|
9.1K
|
6
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Successful GLP Tox Studies in Second Blinding Eye Disease
|
|
Counterfiat
|
21 |
9.1K |
0 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
21
|
9.1K
|
0
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Successful GLP Tox Studies in Second Blinding Eye Disease
|
|
Counterfiat
|
21 |
9.1K |
6 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
21
|
9.1K
|
6
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q2 2024 Investor Webinar Presentation
|
|
Counterfiat
|
23 |
6.8K |
1 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
23
|
6.8K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q2 2024 Investor Webinar Presentation
|
|
Counterfiat
|
23 |
6.8K |
3 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
23
|
6.8K
|
3
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q2 2024 Investor Webinar Presentation
|
|
Counterfiat
|
23 |
6.8K |
8 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
23
|
6.8K
|
8
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q2 2024 Investor Webinar Presentation
|
|
Counterfiat
|
23 |
6.8K |
2 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
23
|
6.8K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
Counterfiat
|
200 |
80K |
6 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
200
|
80K
|
6
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q2 2024 Investor Webinar Presentation
|
|
Counterfiat
|
23 |
6.8K |
8 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
23
|
6.8K
|
8
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q2 2024 Investor Webinar Presentation
|
|
Counterfiat
|
23 |
6.8K |
8 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
23
|
6.8K
|
8
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q2 2024 Investor Webinar Presentation
|
|
Counterfiat
|
23 |
6.8K |
4 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
23
|
6.8K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
Counterfiat
|
529 |
165K |
6 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
529
|
165K
|
6
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q2 Investor Webinar 9 May 2024
|
|
Counterfiat
|
3 |
1.5K |
4 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
3
|
1.5K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
Counterfiat
|
529 |
165K |
2 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
529
|
165K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
Counterfiat
|
529 |
165K |
3 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
529
|
165K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
Counterfiat
|
529 |
165K |
3 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
529
|
165K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Complete response with Cu-67 SAR-bisPSMA
|
|
Counterfiat
|
73 |
23K |
7 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
73
|
23K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Counterfiat
|
527 |
175K |
1 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
527
|
175K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Counterfiat
|
527 |
175K |
6 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
527
|
175K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Complete response with Cu-67 SAR-bisPSMA
|
|
Counterfiat
|
73 |
23K |
3 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
73
|
23K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Complete response with Cu-67 SAR-bisPSMA
|
|
Counterfiat
|
73 |
23K |
3 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
73
|
23K
|
3
|
|
ASX - By Stock
|
CDX |
Re:
Ann: March Quarterly Activities Report
|
|
Counterfiat
|
82 |
15K |
2 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
82
|
15K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
Counterfiat
|
127 |
33K |
0 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
127
|
33K
|
0
|
|
ASX - By Stock
|
CDX |
Re:
Ann: March Quarterly Activities Report
|
|
Counterfiat
|
82 |
15K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
82
|
15K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Kidney Disease Drug Candidate Progressing to Human Trials
|
|
Counterfiat
|
28 |
10K |
0 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
28
|
10K
|
0
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Kidney Disease Drug Candidate Progressing to Human Trials
|
|
Counterfiat
|
28 |
10K |
4 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
28
|
10K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity launches $121 million equity raise
|
|
Counterfiat
|
90 |
36K |
2 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
90
|
36K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity launches $121 million equity raise
|
|
Counterfiat
|
90 |
36K |
5 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
90
|
36K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity launches $121 million equity raise
|
|
Counterfiat
|
90 |
36K |
3 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
90
|
36K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity launches $121 million equity raise
|
|
Counterfiat
|
90 |
36K |
3 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
90
|
36K
|
3
|
|
ASX - By Stock
|
PYC |
Re:
Ann: $74.6 Million Extension of Cash Runway
|
|
Counterfiat
|
15 |
5.3K |
5 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
15
|
5.3K
|
5
|
|
ASX - By Stock
|
A1M |
Re:
A1M: General Comments
|
|
Counterfiat
|
555 |
199K |
3 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
555
|
199K
|
3
|
|
ASX - By Stock
|
CDX |
Re:
Ann: Completion of Wearable Study and New Wearable Patent
|
|
Counterfiat
|
34 |
9.6K |
4 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
34
|
9.6K
|
4
|
|
ASX - By Stock
|
CDX |
Re:
Ann: Completion of Wearable Study and New Wearable Patent
|
|
Counterfiat
|
34 |
9.6K |
1 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
34
|
9.6K
|
1
|
|
ASX - By Stock
|
PYC Biotech |
Re:
PYC Chart and Technical Analysis
|
|
Counterfiat
|
148 |
66K |
8 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
148
|
66K
|
8
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Counterfiat
|
10K |
3.8M |
0 |
03/04/24 |
03/04/24 |
General
|
10K
|
3.8M
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Pillar 1 - FTO (new thread)
|
|
Counterfiat
|
2.9K |
1.0M |
1 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
2.9K
|
1.0M
|
1
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Counterfiat
|
10K |
3.8M |
3 |
28/03/24 |
28/03/24 |
General
|
10K
|
3.8M
|
3
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Counterfiat
|
10K |
3.8M |
1 |
28/03/24 |
28/03/24 |
General
|
10K
|
3.8M
|
1
|
|